Despite a steep 53% decline from its February peak, telehealth provider Hims & Hers is sending a powerful message to the market. The announcement of a substantial new $250 million share repurchase initiative signals the leadership’s firm belief that the company’s equity is significantly undervalued. The critical question for investors is whether this bold financial maneuver can reverse the stock’s downward trajectory.
Financial Strength Underpins Aggressive Buyback
The company’s confidence appears to be backed by solid operational performance. Third-quarter results revealed a robust 49% surge in revenue, reaching nearly $600 million. The subscriber base also expanded considerably, climbing to approximately 2.5 million users. With a projected full-year EBITDA margin exceeding 13%, the firm demonstrates the financial capacity to execute this billion-dollar equivalent commitment to buying back its own shares.
This new authorization arrives just two weeks after the completion of a previous $100 million buyback program. Chief Executive Officer Andrew Dudum justified the move, stating that the management team continues to identify opportunities where the market price fails to adequately reflect the intrinsic value they perceive in the company.
Should investors sell immediately? Or is it worth buying Hims & Hers?
Market Skepticism Amid Sector Headwinds
Why has the market responded with caution to what is ostensibly positive news? The shares are currently trading around €31, a level that sits more than 25% below their 200-day moving average. The stock has been on a persistent decline since hitting its all-time high of €66 in February.
Underlying this investor hesitancy are broader industry challenges. The telehealth sector is navigating a complex regulatory landscape, including recent FDA actions concerning compounded medications. Furthermore, competition within the digital health market is intensifying at a rapid pace, creating additional pressure.
Strategic Patience: A Three-Year Horizon for Value Creation
The newly unveiled repurchase plan is structured to span three years, granting executives considerable flexibility to make tactical acquisitions of shares over time. If the leadership’s assessment of undervaluation is correct, this strategy could ultimately be recognized as a masterstroke. The forthcoming quarterly earnings reports will be crucial in determining if the company can sustain its impressive growth rate. All eyes will be on whether management’s quarter-billion-dollar wager will pay off.
Ad
Hims & Hers Stock: Buy or Sell?! New Hims & Hers Analysis from November 19 delivers the answer:
The latest Hims & Hers figures speak for themselves: Urgent action needed for Hims & Hers investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 19.
Hims & Hers: Buy or sell? Read more here...
